Impact of metabolic syndrome and its components on the tumor aggressiveness of renal cell carcinoma
Open Access
- 16 January 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e47247
Abstract
This retrospective study aimed to assess the impact of metabolic syndrome (MS) and its components on tumor size, Fuhrman grade (FG), and tumor-node-metastasis stage in patients with renal cell carcinoma (RCC). Data from 151 patients who underwent surgery for RCC between January 2010 and April 2018 were retrospectively reviewed. The criteria included blood test results, presence of chronic ailments, and body mass index. Tumor size, FG, and TNM stage were compared. The criteria for defining MS and statistical methods were used for the comparative investigation. Of the 151 patients operated for RCC in our clinic, the prevalence of MS, diabetes mellitus, hypertension (HT), dyslipidemia, and obesity was 27.2%, 29.1%, 41.1%, 64.9%, and 27.2%, respectively. Tumor size was significantly larger, and FG and TNM stages were more advanced in patients with MS than in patients without MS ( P = .046, P = .005, P = .030, respectively). The study revealed a statistically significant increase in tumor size associated with diabetes mellitus, HT, dyslipidemia (DysL), and obesity ( P = .017, P = .007, P < .001, P = .005, respectively). The TNM stage was significantly higher in patients with HT, DysL, and obesity ( P < .001, all of them). In patients undergoing surgery for RCC, MS, and its components showed a statistically significant correlation with tumor size. In addition, HT, DysL, and obesity were associated with a high TNM stage. These findings underscore the potential clinical relevance of addressing the metabolic factors in RCC management.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort StudiesDiabetes Care, 2018
- Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell CarcinomaDiscover Oncology, 2017
- Metabesity and urological cancersUrology Research and Practice, 2017
- Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literatureInternational Journal of Molecular Medicine, 2016
- The Impact of Diabetes Mellitus on Renal Cell Carcinoma PrognosisMedicine, 2015
- Association of hypertension and obesity with renal cell carcinoma risk: a report from the Shanghai Men’s and Women’s Health StudiesCancer Causes & Control, 2015
- The reliability of the National Cholesterol Education Program's Adult Treatment Panel III (NCEP/ATP III) and the International Diabetes Federation (IDF) definitions in diagnosing metabolic syndrome (MetS) among Gaza Strip PalestiniansDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2012
- Diabetes and Risk of Renal Cell CarcinomaJournal of Cancer, 2012
- Urological aspects of the metabolic syndromeNature Reviews Urology, 2011
- Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trialsThe Lancet Oncology, 2011